ResearchMoz

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013

Global Markets Direct
Published Date » 2013-04-17
No. Of Pages » 138
   
 Global Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects.  
   
 
 It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets...
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cutaneous T-Cell Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Cutaneous T-Cell Lymphoma 10
Cutaneous T-Cell Lymphoma Therapeutics under Development by Companies 12
Cutaneous T-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Cutaneous T-Cell Lymphoma Therapeutics - Products under Development by Companies 20
Cutaneous T-Cell Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Cutaneous T-Cell Lymphoma Therapeutics Development 23
Johnson & Johnson 23
Kyowa Hakko Kirin Co., Ltd. 24
Shionogi & Co., Ltd. 25
Seattle Genetics, Inc. 26
Emergent BioSolutions Inc. 27
Novartis AG 28
Eisai Co., Ltd. 29
Onyx Pharmaceuticals, Inc. 30
Mundipharma International Limited 31
Innate Pharma SA 32
Spectrum Pharmaceuticals, Inc. 33
Mondobiotech Holding AG 34
Yaupon Therapeutics, Inc. 35
ELORAC, Inc. 36
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
brentuximab vedotin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
panobinostat - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
carfilzomib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
everolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
mogamulizumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
forodesine hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
mechlorethamine hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pralatrexate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IPH-41 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
zanolimumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
belinostat + [bortezomib] - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
everolimus + panobinostat - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Therapeutic allogeneic lymphocytes program - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
quisinostat - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
bexarotene - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
alefacept - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
naloxone hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
DasKloster-011201 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
DNA IL-12 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
[pralatrexate] + [bexarotene] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SHP-141 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Angeloxin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
resiquimod - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Genetically Modified T Cells 1138 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
interferon gamma-1a - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 95
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 125
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 126
Cutaneous T-Cell Lymphoma - Product Development Milestones 128
Featured News & Press Releases 128
Nov 15, 2012: Elorac Obtains European Orphan Medical Product Designation For Naloxone Hydrochloride Dehydrate For Treatment Of Cutaneous T-cell Lymphoma 128
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 128
Jul 09, 2012: OncoSec Initiates Phase II Clinical Program In Cutaneous T-Cell Lymphoma And Doses First Patient 130
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 131
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 131
May 10, 2012: Seattle Genetics Presents Interim Results From Phase II Trial Of ADCETRIS At Society For Investigative Dermatology Annual Meeting 131
Jan 26, 2012: Seattle Genetics Announces Data From ADCETRIS In Cutaneous T-Cell Lymphoma And Peripheral T-Cell Lymphoma 132
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 134
Jan 18, 2012: Ceptaris Receives Orphan Drug Designation From EMA For Mechlorethamine Gel 134
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride 135

Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137

List of Tables


Number of Products Under Development for Cutaneous T-Cell Lymphoma, H1 2013 10
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Johnson & Johnson, H1 2013 23
Kyowa Hakko Kirin Co., Ltd., H1 2013 24
Shionogi & Co., Ltd., H1 2013 25
Seattle Genetics, Inc., H1 2013 26
Emergent BioSolutions Inc., H1 2013 27
Novartis AG, H1 2013 28
Eisai Co., Ltd., H1 2013 29
Onyx Pharmaceuticals, Inc., H1 2013 30
Mundipharma International Limited, H1 2013 31
Innate Pharma SA, H1 2013 32
Spectrum Pharmaceuticals, Inc., H1 2013 33
Mondobiotech Holding AG, H1 2013 34
Yaupon Therapeutics, Inc., H1 2013 35
ELORAC, Inc., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 43
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 95
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 125
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 126
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products (Contd..1) 127

List of Figures


Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2013 10
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

Upcoming Reports:

Neurotherapeutic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Neurologic disorder can be defined as a change in the functioning of nervous system. These disorders occur due to the structural or biochemical change in the activity of brain, spinal cord and other nerves. Neurologic disorders can be primarily categorized into three main divisions namely central nervous system disorders, peripheral nervous system disorders and autonomous nervous system disorder. Many of the neurologic disorders involve progressive deterioration in physical and mental capabilities that disturbs both patient and patient’s family. Changes in the brain activity are...
Greece: market of plastic tubes, pipes and hoses
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the plastic tubes, pipes and hoses market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the plastic tubes, pipes and hoses market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Video Telemedicine Market - Global Industry Size, Market Share, Trends Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
The term telemedicine refers to the utilization of telecommunication technologies in the healthcare industry. Doctors use such technologies to diagnose or treat a patient remotely. Video telemedicine deals with that part of the telemedicine market, which is done through video conferencing. The global telemedicine market was estimated to be USD 740 million in 2011. The market will grow to reach USD 877.50 million in 2012, and will grow at an estimated CAGR of 18.58% from 2012 to 2018, to reach USD 2440 million by 2018. The U.S and Europe hold the majority of the market...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Does Chewing Gum Lead to Academic Productivity?
Aug 20, 2014  
Could chewing gum actually lead to improved academic productivity? A study conducted recently has found that there may possibly be a link between the two, finally making some headway in a decade-old research. The study called ‘The Effects of Gum Chewing on Math Scores in Adolescents’ was led by Craig Johnston from Baylor College of Medicine in Houston, Texas, and was sponsored by...
German Arms Industrys Outlook Uncertain
Aug 20, 2014  
During a recent meeting between representatives of the German ammunition and arms industry and the German Ministry for Economic Affairs, the unionists discussed concerns about the declining approvals for German arms shipment contracts. Workers’ representatives had, earlier in July 2014, written to the German minister of economic affairs Sigmar Gabriel stating that these curbs on...
Microcontrollers Market Poised to Witness Full-Blown Recovery
Aug 20, 2014  
The microcontrollers industry may well be on the verge of a full-blown recovery thanks to a rebound in sales to automotive and industrial customers. Analysts say that this recovery isn’t limited to the 32-bit market. Signs of growth are also being seen in the 8-bit industry, with a higher inflow of new orders.  The growth has been so encouraging that Arizona-based Microchip...
US Vessel Cape Ray Destroyed Syrias Chemical Weapons
Aug 19, 2014  
RIA Novosti, Monday news stated that teams aboard the MV Cape Ray (US vessel) have completed the task of neutralizing the chemical stockpile materials declared in Syria. This was informed by John Kirby, Pentagon Press Secretary Rear Adm. The Secretary of Defense – Chuck Hagel congratulated the Navy Captain – Rich Dromerhauser ship's crew on completing their task of...
Surge in Bourbon Production
Aug 19, 2014  
America’s bourbon whiskey manufacturer, Kentucky, has taken a decision on hoarding large stockpiles of bourbon whiskey. According to sources, distillers are stocking up the huge quantities of bourbon even before the demand for the same has arisen in the market.  This step of excess production involves a certain risk, but as soon as the market demand for this dominates the...